|
|
Curdlan |
|
Vaxjo ID |
490 |
|
Vaccine Adjuvant Name |
Curdlan |
|
Adjuvant VO ID |
VO_0005767
|
|
Description |
carbohydrate vaccine adjuvant that induces Th1-biased response |
|
Stage of Development |
Research |
|
Location Licensed |
France |
|
Components |
β-1,3–linked glucose |
|
Structure |
linear polymer of β-1,3–linked glucose |
|
Function |
Type: microbial derivative vaccine adjuvant. Target Receptor: C-type lectin domain family 7 member A (Dectin-1). Induces Th1-biased immune profile. Dectin-1 activation overcomes the transcriptional control of the IL-12p35 subunit and allows TLR-induced IL-12p70 secretion by neonatal DCs and further TH1 polarization of neonatal T cells |
| References |
Lemoine et al., 2015: Lemoine S, Jaron B, Tabka S, Ettreiki C, Deriaud E, Zhivaki D, Le Ray C, Launay O, Majlessi L, Tissieres P, Leclerc C, Lo-Man R. Dectin-1 activation unlocks IL12A expression and reveals the TH1 potency of neonatal dendritic cells. The Journal of allergy and clinical immunology. 2015; 136(5); 1355-1368.e1-1368. [PubMed: 25865351].
|
|
